



Diversified Consumer Services | Small Cap
Lotus Eye Hospital & Institute Ltd demonstrates a mixed financial performance. The company shows strong solvency, indicating a healthy balance between debt and equity. Efficiency ratios highlight effective inventory and receivables management, but fixed asset and capital turnover need improvement. While revenue growth is positive, declines in operating profit, EPS, and net income growth raise concerns about long-term sustainability. The company's interest coverage is strong, but dividend coverage is weak. Profitability metrics, such as gross profit margin, ROCE, ROE, and operating margin, are robust, but ROA is just average. Overall, the company exhibits financial strengths in solvency, efficiency and profitability but needs to address weaknesses in growth and financial management to ensure sustained financial health.
Lotus Eye Hospital & Institute Ltd demonstrates a mixed financial performance. The company shows strong solvency, indicating a healthy balance between debt and equity. Efficiency ratios highlight effective inventory and receivables management, but fixed asset and capital turnover need improvement. While revenue growth is positive, declines in operating profit, EPS, and net income growth raise concerns about long-term sustainability. The company's interest coverage is strong, but dividend coverage is weak. Profitability metrics, such as gross profit margin, ROCE, ROE, and operating margin, are robust, but ROA is just average. Overall, the company exhibits financial strengths in solvency, efficiency and profitability but needs to address weaknesses in growth and financial management to ensure sustained financial health.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
369.59
Industry Median
23.43
Small Cap Median
23.43
P/E RATIO
328.53
P/B RATIO
4.05
Industry Median
1.98
Small Cap Median
1.98
P/S RATIO
4.96
Industry Median
2.99
Small Cap Median
2.99
Others
PEG RATIO
-25.67
EV/EBITDA RATIO
50.83
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹118.27 as on Jun 15, 2026.
The company shows positive revenue and asset growth, but declines in operating profit, EPS, and net income growth are concerning. While revenue growth indicates expanding market presence, declining profitability metrics suggest rising costs or inefficiencies. Focus on cost management and operational efficiency is needed to translate revenue growth into improved profitability.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 20.25 | 20.9 | 2.49 | 2.8 | 8.4 |
| Operating Profit Growth Rate | 63.54 | 29.73 | -13.67 | -46.3 | -5.06 |
| Earnings Per Share (EPS) Growth | 90.67 | 37.06 | -28.57 | -74.29 | -88.89 |
| Asset Growth Rate | 4.02 | 2.56 | 5.46 | 4.41 | 18.73 |
| Net Income Growth Rate | 89.81 | 36.91 | -28.68 | -74.57 | -89.19 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Vaidya Sane Ayurved Laboratories Ltd | 7.72 | 23.57 | Undervalued | 15.00 | 4.69 | 9.00 |
| 2 | Maitreya Medicare Ltd | 7.34 | -33.01 | Neutral | -0.46 | -1.96 | -2.47 |
| 3 | Lotus Eye Hospital & Institute Ltd | 6.07 | 328.53 | Overvalued | 3.38 | 0.04 | 0.08 |
| 4 | Nephro Care India Ltd | 5.69 | 43.87 | Neutral | 8.32 | 2.04 | 3.37 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Lotus Eye Hospital & Institute Ltd is a prominent South Indian eye care chain providing comprehensive ophthalmic services. Specializing in advanced treatments like cataract and refractive surgeries, glaucoma, and retina care, it leverages modern technology and skilled medical professionals. The company focuses on delivering quality patient care and maintaining a strong regional presence in the specialized healthcare sector.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Lotus Eye Hospital & Institute Ltd's P/E ratio (TTM) is 369.59, compared to the industry median of 23.43 and large cap median of 23.43.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Lotus Eye Hospital & Institute Ltd's P/B ratio is 4.05, compared to the industry median of 1.98 and large cap median of 1.98.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Lotus Eye Hospital & Institute Ltd's P/S ratio is 4.96, compared to the industry median of 2.99 and large cap median of 2.99.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Lotus Eye Hospital & Institute Ltd's PEG ratio is -25.67.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Lotus Eye Hospital & Institute Ltd's EV/EBITDA ratio is 50.83.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Lotus Eye Hospital & Institute Ltd's ROE is 0.13%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Lotus Eye Hospital & Institute Ltd's ROA is 4.09%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Lotus Eye Hospital & Institute Ltd's ROCE is 1.16%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Lotus Eye Hospital & Institute Ltd's operating margin is 6.29%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Lotus Eye Hospital & Institute Ltd's net margin is 0.15%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Lotus Eye Hospital & Institute Ltd's current ratio is 2.12.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Lotus Eye Hospital & Institute Ltd's debt-to-equity ratio is 0.25.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Lotus Eye Hospital & Institute Ltd's interest coverage ratio is 0.94.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Lotus Eye Hospital & Institute Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Lotus Eye Hospital & Institute Ltd's EPS is -88.89.
(Source line: "Ratios as of 22 Nov 2026, based on last traded price of ₹118.27. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1999 (as Lotus Eye Care Hospital Ltd.)
Headquarters: Coimbatore, Tamil Nadu
Core Offerings: Cataract surgery, Refractive surgeries (LASIK, SMILE), Glaucoma treatment, Retina services, Oculoplasty
Stock Listing: NSE (LOTUSEYE), BSE (532998)
Promoter: Dr. S.K. Sundaramoorthy & Family
1999: Incorporated as Lotus Eye Care Hospital Ltd. in Coimbatore, Tamil Nadu. 2006: Went public with an Initial Public Offering (IPO). Present: Operates as a chain of super-specialty eye hospitals across South India, offering advanced ophthalmic treatments and diagnostic services.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Hospital Services (Ophthalmology) | 100% | N/A (Integrated operations) |
Cataract & Refractive Surgeries: A core revenue driver, performing a high volume of cataract removals and vision correction procedures like LASIK, SMILE, and ICL.
General Ophthalmic Consultations & Diagnostics: Provides outpatient services, comprehensive eye check-ups, and advanced diagnostic tests for various eye conditions.
Specialty Eye Care: Offers super-specialized treatments for conditions such as Glaucoma, Retina, Cornea, Oculoplasty, and Pediatric Ophthalmology, utilizing state-of-the-art equipment.
Optical & Pharmacy Services: In-house optical outlets offering a wide range of eyeglasses, contact lenses, and pharmaceutical products related to eye care.
Dr. S. K. Sundaramoorthy: Chairman & Managing Director. A highly experienced ophthalmologist and the founder of Lotus Eye Hospital, he provides strategic direction and clinical leadership.
No major subsidiaries reported.
Bonus Issue (1:2) in 2022; Stock Split (Rs.10 to Re.1 face value) in 2017.
The Lotus Eye Hospital & Institute Ltd share price today is ₹118.27 on NSE (LOTUSEYE), as of 22 Nov 2026.
As of 22 Nov 2026, Lotus Eye Hospital & Institute Ltd share price is ₹118.27, with previous close ₹118.27. Today's range is ₹118.27 to ₹118.27. The 52-week range is ₹97.59 to ₹147.
As of today, Lotus Eye Hospital & Institute Ltd's market cap is ₹246 crore (Small Cap).
Lotus Eye Hospital & Institute Ltd's current P/E ratio is 369.59, compared to the DIVERSIFIED CONSUMER SERVICES sector average of 46.50.
Lotus Eye Hospital & Institute Ltd's current P/B ratio is 4.05.
Lotus Eye Hospital & Institute Ltd's current dividend yield is N/A. Last dividend of ₹0.10 per share was declared on 22-Sep-2023.
Lotus Eye Hospital & Institute Ltd's EPS (TTM) is ₹-88.89.
Lotus Eye Hospital & Institute Ltd is a prominent South Indian eye care chain providing comprehensive ophthalmic services. Specializing in advanced treatments like cataract and refractive surgeries, glaucoma, and retina care, it leverages modern technology and skilled medical professionals. The company focuses on delivering quality patient care and maintaining a strong regional presence in the specialized healthcare sector.
Lotus Eye Hospital & Institute Ltd is promoted by Dr. S.K. Sundaramoorthy & Family, holding 40.14% as of 22 Nov 2026.
Lotus Eye Hospital & Institute Ltd is listed on NSE (LOTUSEYE) and BSE (532998). Its next quarterly results are expected on August 2024 (for Q1 FY25).